Allergan Inc. said Wednesday that its second-quarter profit more than doubled from a year ago, thanks to increased sales of its eye treatments and core Botox wrinkle-reducing drug.
Irvine-based Allergan earned $74.2 million in the second quarter, up from $33.4 million in the year-ago quarter. Restructuring costs affected its results a year ago.
Revenue shot up 33% to $787 million in the period, fueled by wrinkle fillers and other products picked up in Allergan’s $3.2 billion buy of Inamed Corp.
Second-quarter Botox sales were up 17% to $379 million. Eye care sales also jumped 17% to $248 million.
Allergan slightly raised its 2006 profit forecast to $536.6 million to $545.5 million, including stock options expensing.
The company also said its sales should be $2.87 billion and $3 billion, up from an earlier projection of $2.83 billion to $2.97 billion.
Shares of Allergan were up 2.2% to $109.50 in trading Wednesday.
